What is the NOAEL for 4-Aminobenzoic acid?
4-Aminobenzoic acid has 67 NOAEL studies in the database. The lowest reported value is 0 uL/min/10^6 cells in Human. Source: NTP_ICE_adme_parameters.
Also known as: 1-Amino-4-carboxybenzene, BRN 0471605, Caswell No. 033B, EINECS 205-753-0, EPA Pesticide Chemical Code 233300 (+15 more)
CAS 150-13-0
4-Aminobenzoic acid (CAS 150-13-0) is a chemical substance; key hazard signal: IARC Group 3. Key regulatory status: REACH registered, 5 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from EPA ToxValDB, EPA CPDat, AICIS, SCCS, IARC, ECHA REACH.
CAS, identifiers, formula, and alternate names for the matched substance record.
Carcinogenic hazard classification from IARC monograph evaluations.
| Group | Meaning | Evaluated | Volume |
|---|---|---|---|
| Group 3 | Not classifiable | 1987 | 16, Sup 7 |
Industrial and product-use categories associated with this substance.
Inventory, screening, and regulatory list matches from public chemical databases.
| List | Keyword | Source |
|---|---|---|
| banned; Europe; Personal care | European Commission | CosIng |
| inert_ingredient; non_food_use; Pesticides | EPA | CPCat |
| Canada; pharmaceutical | DrugBank | DrugBank |
| food_additive; Substances Added to Food (formerly EAFUS) (2/2019) | FDA | United States Food and Drug Administration (FDA) |
| Europe; Personal care | Danish Environmental Protection Agency | Danish EPA |
Toxicology endpoints rendered from public NOAEL study rows.
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 0.1 | % | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 1 | % | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 108 | - | - | oral | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 108 | - | - | oral | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| >200 | ug/mL | CD86, EC150 | Dermal | - | NTP_ICE_skin_sensitization |
| >1000 | ug/mL | CV75 | Dermal | - | NTP_ICE_skin_sensitization |
| - | uL/min/10^6 cells | Clint | - | Human | NTP_ICE_adme_parameters |
| =10.58 | mg/m3 | DNEL systemic | inhalation | Human | ToxValDB_GESTIS_DNEL |
| 1 | % | Depletion Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 1.4 | % | Depletion Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 3.9 | % | Depletion Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 4.6 | % | Depletion Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 5.9 | % | Depletion Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 10.6 | % | Depletion Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 10.7 | % | Depletion Cys | Dermal | - | NTP_ICE_skin_sensitization |
| - | % | Depletion Lys | Dermal | - | NTP_ICE_skin_sensitization |
| 0.1 | % | Depletion Lys | Dermal | - | NTP_ICE_skin_sensitization |
| 0.4 | % | Depletion Lys | Dermal | - | NTP_ICE_skin_sensitization |
| 0.5 | % | Depletion Lys | Dermal | - | NTP_ICE_skin_sensitization |
| 0.6 | % | Depletion Lys | Dermal | - | NTP_ICE_skin_sensitization |
| 0.7 | % | Depletion Lys | Dermal | - | NTP_ICE_skin_sensitization |
| 0.9 | % | Depletion Lys | Dermal | - | NTP_ICE_skin_sensitization |
| 0.35 | % | Depletion Lys + Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 0.45 | % | Depletion Lys + Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 1.05 | % | Depletion Lys + Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 2.3 | % | Depletion Lys + Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 2.35 | % | Depletion Lys + Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 2.4 | % | Depletion Lys + Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 3.2 | % | Depletion Lys + Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 5.55 | % | Depletion Lys + Cys | Dermal | - | NTP_ICE_skin_sensitization |
| 5.6 | % | Depletion Lys + Cys | Dermal | - | NTP_ICE_skin_sensitization |
| >2000 | uM | EC1.5 | Dermal | - | NTP_ICE_skin_sensitization |
| TL2TJE8QTX | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| TL2TJE8QTX | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| TL2TJE8QTX | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| TL2TJE8QTX | UNII | FDA UNII substance identifier | - | - | openFDA substances |
| 0.766 | fraction | Fu | - | Human | NTP_ICE_adme_parameters |
| 3 | IARC group | IARC carcinogenicity classification | - | - | IARC Monographs |
| 3 | IARC group | IARC carcinogenicity classification | - | - | IARC Monographs |
| 3 | IARC group | IARC carcinogenicity classification | - | - | IARC Monographs |
| 3 | unitless | IARC group | - | - | NTP_ICE_cancer |
| >2400 | uM | IC50 | Dermal | - | NTP_ICE_skin_sensitization |
| 1.107 | ratio | Imax | Dermal | - | NTP_ICE_skin_sensitization |
| 1.21 | ratio | Imax | Dermal | - | NTP_ICE_skin_sensitization |
| 1.23 | ratio | Imax | Dermal | - | NTP_ICE_skin_sensitization |
| - | % | Incidence of positive responses | Dermal | Human | NTP_ICE_skin_sensitization |
| 15520 | ug/cm2 | Induction dose per skin area | Dermal | Human | NTP_ICE_skin_sensitization |
| - | unitless | Model Score | - | - | NTP_ICE_endocrine |
| =0.1 | % | NOAEL | oral | rat | SCCS_vision_codex |
| =0.1 | % | NOAEL | oral | rat | SCCS_vision_codex |
Showing 50 of 67 studies
Registration status from the ECHA REACH registered substances database.
| Status | Name | EC Number | Link |
|---|---|---|---|
| Registered | 4-aminobenzoic acid | 205-753-0 | ECHA overview → |
Australian industrial chemicals inventory status and applicable conditions.
EU Scientific Committee opinions tied to the matched substance.
| Opinion | Date | Conclusion | Max Conc. | Concerns |
|---|---|---|---|---|
| SCCP/0937/05 | 20 June 2006 | safe | up to 5% | Photocontact allergic reactions reported; skin sensitisation risk; declining use in favour of alternatives; no mutagenic/carcinogenic/teratogenic risk identified; possible thyroid disrupting activity (not confirmed) |
Same-CAS cosmetic ingredient record for cross-vertical context.
Same-CAS pharmaceutical records from drug and bioactivity sources.
4-Aminobenzoic acid has 67 NOAEL studies in the database. The lowest reported value is 0 uL/min/10^6 cells in Human. Source: NTP_ICE_adme_parameters.
4-Aminobenzoic acid appears on 5 regulatory/inventory lists including banned; Europe; Personal care, inert_ingredient; non_food_use; Pesticides, Canada; pharmaceutical, and 2 more. Source: EPA CPDat.
4-Aminobenzoic acid is classified by IARC as Group 3 — not classifiable as to its carcinogenicity to humans (evaluated 1987). Source: IARC Monographs on the Identification of Carcinogenic Hazards to Humans.
Yes, 4-Aminobenzoic acid is also indexed as a cosmetic ingredient under the name PABA. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Safety data is sourced from EPA ToxValDB, EPA CPDat, AICIS (Australian Industrial Chemicals Introduction Scheme), EPA DSSTox, IARC Monographs, ECHA REACH, CosIng / Ingredients DB, ChEMBL / DailyMed. All data traces to primary regulatory sources and is updated from official government databases.
4-Aminobenzoic acid also appears in cosmetics, pharmaceutical databases.